[
  {
    "ts": "2025-10-16T17:13:06+00:00",
    "headline": "Dividend Stock Deathmatch: Aristocrats, Kings, Zombies or REITs? Reliable Income vs. Yield Chasing",
    "summary": "Not all dividend stocks are created equal, and in this quick lesson, Rick Orford explains the difference between popular types of income-generating investments.",
    "url": "https://www.barchart.com/story/news/35502777/dividend-stock-deathmatch-aristocrats-kings-zombies-or-reits-reliable-income-vs-yield-chasing",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "7775ce2f-f9ff-3af4-b3da-869c641fa894",
      "content": {
        "id": "7775ce2f-f9ff-3af4-b3da-869c641fa894",
        "contentType": "STORY",
        "title": "Dividend Stock Deathmatch: Aristocrats, Kings, Zombies or REITs? Reliable Income vs. Yield Chasing",
        "description": "",
        "summary": "Not all dividend stocks are created equal, and in this quick lesson, Rick Orford explains the difference between popular types of income-generating investments.",
        "pubDate": "2025-10-16T17:13:06Z",
        "displayTime": "2025-10-16T17:13:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/ab9e04a794afafc6608c362fb3e6593b",
          "originalWidth": 1600,
          "originalHeight": 933,
          "caption": "Dividend calculator by Fox_Ana via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bDV2p4ofJfclezlIx7mR_g--~B/aD05MzM7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/ab9e04a794afafc6608c362fb3e6593b.cf.webp",
              "width": 1600,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2TOSB0FBIyvQuGW04Qzx9w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/ab9e04a794afafc6608c362fb3e6593b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/35502777/dividend-stock-deathmatch-aristocrats-kings-zombies-or-reits-reliable-income-vs-yield-chasing",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dividend-stock-deathmatch-aristocrats-kings-171306023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "ADM"
            },
            {
              "symbol": "MCD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T15:31:27+00:00",
    "headline": "Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says",
    "summary": "Abbott Laboratories' (ABT) underlying business momentum is intact heading into 2026 despite mixed Q3",
    "url": "https://finance.yahoo.com/news/abbott-labs-apos-business-momentum-153127492.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c267f843-eb09-3273-94e9-178633bf3fac",
      "content": {
        "id": "c267f843-eb09-3273-94e9-178633bf3fac",
        "contentType": "STORY",
        "title": "Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says",
        "description": "",
        "summary": "Abbott Laboratories' (ABT) underlying business momentum is intact heading into 2026 despite mixed Q3",
        "pubDate": "2025-10-16T15:31:27Z",
        "displayTime": "2025-10-16T15:31:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-labs-apos-business-momentum-153127492.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-labs-apos-business-momentum-153127492.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T11:49:00+00:00",
    "headline": "Abbott’s strong Q3 medtech performance offset by diagnostic weakness",
    "summary": "Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China headwinds impacting overall performance.",
    "url": "https://www.medicaldevice-network.com/news/abbott-strong-q3-medtech-performance-offset-by-diagnostic-weakness/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "e638173e-ebf7-3f61-a356-07de86a249dd",
      "content": {
        "id": "e638173e-ebf7-3f61-a356-07de86a249dd",
        "contentType": "STORY",
        "title": "Abbott’s strong Q3 medtech performance offset by diagnostic weakness",
        "description": "",
        "summary": "Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China headwinds impacting overall performance.",
        "pubDate": "2025-10-16T11:49:00Z",
        "displayTime": "2025-10-16T11:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/84b9689a46d1e824759ffe46851ac06a",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Abbott achieved Q3 2025 revenues of $11.37bn",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7tTl7bmNBY0YW_Ybt2D2GA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/84b9689a46d1e824759ffe46851ac06a.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dKyXPAcqVzR7YJy1FTWMyA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/84b9689a46d1e824759ffe46851ac06a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/abbott-strong-q3-medtech-performance-offset-by-diagnostic-weakness/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strong-q3-medtech-performance-114900596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T10:45:00+00:00",
    "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
    "summary": "Investors should be able to count on these stocks to deliver steady and growing income over the long term.",
    "url": "https://www.fool.com/investing/2025/10/16/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d2ef91fb-2abb-34d2-9b39-d31ed84a854c",
      "content": {
        "id": "d2ef91fb-2abb-34d2-9b39-d31ed84a854c",
        "contentType": "STORY",
        "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
        "description": "",
        "summary": "Investors should be able to count on these stocks to deliver steady and growing income over the long term.",
        "pubDate": "2025-10-16T10:45:00Z",
        "displayTime": "2025-10-16T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c7f52194b1b5967358efff15f1b012b4",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "AbbVie sign in front of a building.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Sc4RWnMMNGOU7ZQJTpYmUg--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c7f52194b1b5967358efff15f1b012b4.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yeymr60TIM0d74TKpQqG8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c7f52194b1b5967358efff15f1b012b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/16/want-decades-of-passive-income-3-stocks-to-buy-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/want-decades-passive-income-3-104500048.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T09:58:00+00:00",
    "headline": "Company News for Oct 16, 2025",
    "summary": "Companies In The News Are: HWC, PGR, ABT, ASML.",
    "url": "https://finance.yahoo.com/news/company-news-oct-16-2025-095800830.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d7727127-04c5-38d0-bbc8-c23fabf7e46a",
      "content": {
        "id": "d7727127-04c5-38d0-bbc8-c23fabf7e46a",
        "contentType": "STORY",
        "title": "Company News for Oct 16, 2025",
        "description": "",
        "summary": "Companies In The News Are: HWC, PGR, ABT, ASML.",
        "pubDate": "2025-10-16T09:58:00Z",
        "displayTime": "2025-10-16T09:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9f7296fade0c729cbae8baf4df367222",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vAG7Ez9jb7JTt_ns5ykz0A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f7296fade0c729cbae8baf4df367222.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vwUeqqre14obWSY83ppBxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f7296fade0c729cbae8baf4df367222.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/company-news-oct-16-2025-095800830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/company-news-oct-16-2025-095800830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ASML.AS"
            },
            {
              "symbol": "HWC"
            },
            {
              "symbol": "PGR"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T09:09:00+00:00",
    "headline": "Sepsis Diagnostics Research Report 2025: Global Market to Reach $1.39 Billion by 2029 - Increased Adoption of Point-of-care Testing and Strategic Collaborations Boosting Growth",
    "summary": "The global sepsis diagnostics market, valued at USD 835.40 million in 2023, is projected to reach USD 1.39 billion by 2029, driven by advancements in healthcare infrastructure and awareness of sepsis, a critical life-threatening condition. The market is expected to grow at a CAGR of approximately 9% from 2024 to 2029, with increased adoption of point-of-care testing and strategic collaborations boosting growth. Key segments include microbiology, molecular diagnostics, and point-of-care tests, wi",
    "url": "https://finance.yahoo.com/news/sepsis-diagnostics-research-report-2025-090900486.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "656ae61a-9e8c-3c00-bcab-beda0a7e41c2",
      "content": {
        "id": "656ae61a-9e8c-3c00-bcab-beda0a7e41c2",
        "contentType": "STORY",
        "title": "Sepsis Diagnostics Research Report 2025: Global Market to Reach $1.39 Billion by 2029 - Increased Adoption of Point-of-care Testing and Strategic Collaborations Boosting Growth",
        "description": "",
        "summary": "The global sepsis diagnostics market, valued at USD 835.40 million in 2023, is projected to reach USD 1.39 billion by 2029, driven by advancements in healthcare infrastructure and awareness of sepsis, a critical life-threatening condition. The market is expected to grow at a CAGR of approximately 9% from 2024 to 2029, with increased adoption of point-of-care testing and strategic collaborations boosting growth. Key segments include microbiology, molecular diagnostics, and point-of-care tests, wi",
        "pubDate": "2025-10-16T09:09:00Z",
        "displayTime": "2025-10-16T09:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sepsis-diagnostics-research-report-2025-090900486.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sepsis-diagnostics-research-report-2025-090900486.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "SHL.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T05:31:56+00:00",
    "headline": "ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook",
    "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/abt-q3-deep-dive-q3-053156194.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "e1c607ef-6b29-3cdf-a1c8-7199976fd17e",
      "content": {
        "id": "e1c607ef-6b29-3cdf-a1c8-7199976fd17e",
        "contentType": "STORY",
        "title": "ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook",
        "description": "",
        "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.",
        "pubDate": "2025-10-16T05:31:56Z",
        "displayTime": "2025-10-16T05:31:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABT Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kbpelHm2loJ7pwtgnrVvNw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_TGsH1VQUVpMOlMxL72Mnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abt-q3-deep-dive-q3-053156194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abt-q3-deep-dive-q3-053156194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T00:30:29+00:00",
    "headline": "Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast",
    "summary": "Abbott Laboratories (ABT) reported net profit margins of 31.8%, a significant jump from last year’s 14%. EPS grew sharply over the past year, up 142%, well above its five-year average annual growth rate of 18.1%. Despite this exceptional profit performance, the earnings outlook now points to a forecast decline of 7.1% per year over the next three years, setting up a tension between recent growth and future expectations. See our full analysis for Abbott Laboratories. Next, we will put these...",
    "url": "https://finance.yahoo.com/news/abbott-abt-margin-surge-reinforces-003029875.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7f66a5dd-2193-310b-87e2-d2912b312c33",
      "content": {
        "id": "7f66a5dd-2193-310b-87e2-d2912b312c33",
        "contentType": "STORY",
        "title": "Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast",
        "description": "",
        "summary": "Abbott Laboratories (ABT) reported net profit margins of 31.8%, a significant jump from last year’s 14%. EPS grew sharply over the past year, up 142%, well above its five-year average annual growth rate of 18.1%. Despite this exceptional profit performance, the earnings outlook now points to a forecast decline of 7.1% per year over the next three years, setting up a tension between recent growth and future expectations. See our full analysis for Abbott Laboratories. Next, we will put these...",
        "pubDate": "2025-10-16T00:30:29Z",
        "displayTime": "2025-10-16T00:30:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7zJOBZ6wPnYKbKPRmWh.qQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc9EgsXKjWnUzlOQpxWhqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-abt-margin-surge-reinforces-003029875.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-abt-margin-surge-reinforces-003029875.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]